MASH & MASLD CRO Services

Tell us about your study

We’ll connect you with the right liver and metabolic experts.

Complex Endpoints Require Integrated Expertise

Worldwide combines integrated liver and metabolic expertise, in-house biopsy management, and experience with both histologic and non-invasive endpoints to support modern MASH and MASLD development. This coordinated approach helps sponsors navigate evolving regulatory expectations, reduce operational complexity, and generate high-quality data with confidence.

Endpoint Strategy in a Post-Approval Field

As approved therapies reshape the MASH landscape, new programs require clear scientific differentiation and endpoint strategies that extend beyond biopsy alone. Worldwide combines liver and metabolic expertise to support histologic, biomarker, imaging, and non-invasive endpoint approaches.

Patient Stratification and Biomarker Precision

F2/F3 and F4 populations present distinct scientific and operational considerations that directly affect study design and execution. Worldwide applies rigorous oversight of stratification, biomarker assessment, and non-invasive testing across sites and central laboratories to support accurate patient selection and high-quality endpoint data. 

GLP-1 and Obesity Overlap in Program Design

The growing overlap between obesity, GLP-1 therapies, and MASH requires integrated liver and metabolic expertise. Worldwide supports programs with coordinated scientific leadership and experience incorporating MRI-PDFF, non-invasive assessments, and emerging endpoint strategies into modern MASH trial design. 

Your Program, Supported by One Dedicated Liver Team

Sponsors work with the same liver-experienced scientific, medical, and operational leaders throughout the life of the program. With more than 150 years of combined liver disease research experience, Worldwide provides the continuity, expertise, and strategic partnership needed to guide complex MASH and MASLD studies from startup through final results. 

What Worldwide’s Liver Programs Have Delivered

A global liver development track record spanning indications, phases, and geographies, from early-phase clinical research through multinational Phase III studies. Worldwide combines scientific expertise, operational rigor, and integrated liver-metabolic leadership to support successful program execution at every stage of development.

1,690

Subjects

150

Sites

150+

Years of Combined Liver Experience

500+

Established Liver Site Partnerships

Reduced Risk Across Access, Endpoints & Delivery Model

Site Access & Recruitment Depth

More than 500 established liver site partnerships provide direct access to experienced MASH and MASLD investigators, supporting faster startup, stronger recruitment performance, and efficient execution across global Phase III programs.

Biopsy Management & Non-Invasive Endpoints

Worldwide’s dedicated liver team oversees biopsy collection and management, while MRI-PDFF, MRE, FibroScan®, and biomarker-based endpoint strategies are coordinated under the same scientific leadership. This integrated approach supports consistent endpoint quality, operational efficiency, and data integrity.

Full-Service, FSP, & Hybrid Delivery

Whether you need a fully outsourced MASH program or targeted functional support, Worldwide provides a dedicated liver team that stays with your study from startup through final analysis. The result is greater flexibility, consistent expertise, and a partnership model that scales alongside your program. 

Your Questions Answered

We’ve answered the questions sponsors ask most often about MASH and MASLD clinical development. If your question isn’t covered here, our liver disease experts are available to discuss your program’s specific scientific, regulatory, and operational needs. 

Worldwide’s MASH experience spans Phase I-III development, including a 1,690-subject Phase III study across 150 sites and multiple global Phase II programs. Our teams support biopsy management, MRI-PDFF, FibroScan®, biomarker composite scoring, and integrated liver-metabolic development strategies across every stage of clinical development.

The MASH landscape is constantly changing alongside regulatory expectations, approved therapies, and emerging non-invasive technologies, which change clinical development expectations. Worldwide’s experts monitor FDA and EMA guidance to incorporate it into trial design from the outset. Sponsors require approaches and non-invasive strategies that provide a comprehensive understanding of treatment effect. Worldwide helps sponsors design robust, sustainable programs, drawing from our expertise in endpoint strategy and future planning.

Worldwide manages liver biopsy collection, processing, tracking and interpretation within our dedicated liver team rather than relying on fragmented outsourcing models. Biopsy oversight is integrated with MRI-PDFF, MRE and FibroScan imaging, as well as key biomarker assessments including MASH Fibrosis Score, FIB-4, APRI, FibroSURE/FibroTest and ELF. By bringing centralized biopsy management, AI-assisted histopathology review and scientific leadership under a single operational framework, we help ensure consistency, quality and endpoint integrity across MASH and MASLD programs.

Screen failure runs higher in IgA nephropathy than most enrollment models assume, and competition for biopsy-confirmed patients is heaviest in the U.S. A pre-selected pool of sites gives the program room to move when rates run high, supported by site-level recruitment strategies, patient education materials and patient reimbursement services. On a Phase II cross-over study, that approach closed enrollment 6 months ahead of schedule across 30 sites in 6 countries.